Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression

Acta Oncologica

Volumn 49, Issue 8, 2010, Pages 1235-1245

  Yap, Kevin Yi Lwern ^a   Ho, Yasmin Xiu Xiu ^a   Chui, Wai Keung ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BUSULFAN; CAPECITABINE; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; FLUVOXAMINE; GEMCITABINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MIRTAZAPINE; PEMETREXED; PENTOSTATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; TREOSULFAN; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; COMPUTER PROGRAM; DATA BASE; DEPRESSION; DRUG DOSE REGIMEN; HUMAN; MEDLINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 84984535800     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841861003801130     Document Type: Article

References (55)

1. Newport DJ, Nemeroff CB. Assessment and treatment of depression in the cancer patient. J Psychosom Res 1998;45:215-37.
2. Spiegel D, Giese-Davis J. Depression and cancer: Mechanisms and disease progression. Biol Psychiatry 2003;54:269-82.
3. Onitilo AA, Nietert PJ, Egede LE. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 2006;28:396-402.
4. Lim L. Diagnosis and management of depression in terminal cancer. SGH Proceed 2007;16:88-96.
5. Gross AF, Smith FA, Stern TA. Is depression an appropriate response to having cancer? A discussion of diagnostic criteria and treatment decisions. Prim Care Companion J Clin Psychiatry 2007;9:382-7.
6. Grassi L, Rosti G. Psychosocial morbidity and adjustment to illness among long-term cancer survivors. A six-year followup study. Psychosomatics 1996;37:523-32.
7. Spiegel D, Kato PM. Psychosocial influences on cancer incidence and progression. Harv Rev Psychiatry 1996;4:10-26.
8. Polsky D, Doshi JA, Marcus S, Oslin D, Rothbard A, Thomas N, et al. Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med 2005;165:1260-6.
9. Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized? Crit Rev Oncol Hematol 2005;55:117-42.
10. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Jones RD, Berard RM, et al. Consensus statement on depression, anxiety, and oncology. J Clin Psychiatry 2001;62(Suppl 8):64-7.
11. Beijnen JH, Schellens J H M. Drug interactions in oncology. Lancet Oncol 2004;5:489-96.
12. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998;45:539-44.
13. Tatro DS. Drug interaction facts: The authority on drug interactions. 2008 ed. St. Louis, MO: Facts & Comparisons;s 2008.
14. Preskorn S, Werder S. Detrimental antidepressant drug-drug interactions: Are they clinically relevant? Neuropsychopharmacology 2006;31:1605-12.
15. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clin Ther 2008;30:1206-27.
16. Yap KY-L, Chen YZ, Chui WK, Chan A. Oncoinformatics for the healthcare professional: Oncology databases and blogs. Internet J Oncol 2009 [cited 2009 Oct. 8]; 6. Available from: http://www.ispub.com/journal/the-internet-journal- of-oncology/volume-6-number-1-36/article/oncoinformatics-for-the-healthcare- professional-oncology-databases-and-blogs.html.
17. Scanlon JH, Wieners B. The internet cloud. [cited 2009 Aug. 29]. Available from: http://www.thestandard.com/article/0, 1902, 5466, 00.html.
18. Hansten PD. Drug interaction management. Pharm World Sci 2003;25:94-7.
19. Grönroos PE, Irjala KM, Huupponen RK, Scheinin H, Forsström J, Forsström JJ. A medication database-a tool for detecting drug interactions in hospital. Eur J Clin Pharmacol 1997;53:13-7.
20. American Society of Health-System Pharmacists. AHFS Drug Information website. [cited 2009 May 27]. Available from: http://www.ahfsdruginformation. com.
21. British Medical Association, Royal Pharmaceutical Society of Great Britain. Digital British National Formulary. [cited 2009 May 27]. Available from: http://www.bnf.org.
22. ™. [cited 2009 May 27]. Available from: http://www.lexi.com.
23. ® Healthcare Series [internet database]. [cited 2009 Aug. 8]. Available from: http://www.micromedex. com.
24. Geraci D. Web-based medication resources for parents. [cited 2009 Aug. 29]. Available from: http://www.bpkids.org/site/News2?page=NewsArticle&id= 7657.
25. Rothman D. Online drug interaction checkers. [cited 2009 Aug. 29]. Available from: http://davidrothman. net/2008/01/16/online-drug-interaction- checkers/.
26. Eysenbach G. Consumer health informatics. BMJ 2000;320(7251):1713-6.
27. Yap KY-L, Kuo EY, Lee J J J, Chui WK, Chan A. An oncoinformatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: An overview of the OncoRx project. Support Care Cancer 2010;18(7):883-891.
28. Yap KY, Chan A, Chui WK, Chen YZ. Cancer informatics for the clinician: An interaction database for chemotherapy regimens and antiepileptic drugs. Seizure 2010;19(1):59-67.
29. American Society of Health-System Pharmacists. AHFS Drug Information. 2007 ed. Bethesda, MD: American Society of Health-System Pharmacists Inc.; 2007.
30. British Medical Association, Pharmaceutical Society of Great Britain. British National Formulary. 53rd ed. London, UK: BMJ Publishing Group Ltd & RPS Publishing; 2007.
31. Hansten PD, Horn JR. Hansten and Horn's Drug Interactions Analysis and Management. 3rd ed. Vancouver, Washington: Lippincott Williams & Wilkins; 2008.
32. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook with international trade names index. 15th ed. Hudson, OH: Lexi-comp Inc.; 2007-2008.
33. Solimando D A J. Drug information handbook for oncology. 6th ed. Hudson, OH: Lexi-comp; 2007.
34. BC Cancer Agency. BCCA cancer drug manual. [cited 2009 Aug. 8]. Available from: http://www.bccancer.bc.ca/HPI/DrugDatabase/default.htm.
35. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34(Database issue): D668-D672.
36. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, et al. Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenomics J 2001;1:167-70.
37. ® Healthcare Series (version 5.1) [intranet database]. [cited 2009 Aug. 8]. Available from: http://www.thomsonhc.com/hcs/librarian/PFPUI/fV1mNyY303TXxR.
38. UpToDate Inc. UpToDate Online 16.2 [intranet database]. [cited 2009 Apr. 13]. Available from: http://www.uptodateon line.com.
39. Healthwise Incorporated. AOL Health Drug Interaction Checker. [cited 2008 Mar. 18]. Available from: http://drugchecker.aol.com/hwrxic/home/index.aspx.
40. Gold Standard Inc. Caremark Drug Interactions. [cited 2009 Aug. 8]. Available from: http://cpref.gsm.com/inter.asp?r=8084.
41. Discovery Communications LLC. Discovery Health drug interaction checker. [cited 2008 Mar. 18]. Available from: http://health.discovery.com/webapps/ drugchecker.do?jspLetter=A.
42. ™. [cited 2009 Aug. 8]. Available from: http://www.doublecheckmd.com.
43. ™ drug interactions checker. [cited 2008 Oct. 31]. Available from: http://www.drugs.com/drug-interactions. html.
44. Express Scripts Inc. Drug Digest interactions checker. [cited 2008 Jan 21]. Available from: http://www.drugdigest.org/DD/Interaction/ChooseDrugs.
45. ™) Drug Interaction Tool. [cited 2008 Mar. 18]. Available from: http://pdrhealth.com/health/health-tools-druginteractions.aspx.
46. ® drug interaction checker. [cited 2008 Jan 21]. Available from http://www.medscape.com/druginfo/druginterchecker.
47. ™ web hosting. [cited 2009 May 27]. Available from: http://www.dreamhost.com.
48. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen- nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-96.
49. Sandoz Inc. Fluvoxamine maleate tablet [product information]. Princeton, NJ; 2007.
50. Anttila AK, Rasanen L, Leinonen EV. Fluvoxamine augmentation increases serum mirtazapine concentrations three-to fourfold. Ann Pharmacother 2001;35:1221-3.
51. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42.
52. Boyce R, Collins C, Horn J, Kalet I. Computing with evidence Part I: A drug-mechanism evidence taxonomy oriented toward confidence assignment. J Biomed Inform 2009;42:979-89.
53. Boyce R, Collins C, Horn J, Kalet I. Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform 2009;42:990-1003.
54. ® kit (temsirolimus) injection [product information]. Philadelphia, PA; 2008.
55. Boyer C, Selby M, Scherrer JR, Appel RD. The Health On the Net Code of Conduct for medical and health websites. Comput Biol Med 1998;28:603-10.